BioMarin Pharmaceutical Inc. (BMRN) - Financial and Strategic SWOT Analysis Review

Date: May 24, 2016
Pages: 66
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BDF56652184EN
Leaflet:

Download PDF Leaflet

BioMarin Pharmaceutical Inc. (BMRN) - Financial and Strategic SWOT Analysis Review
BioMarin Pharmaceutical Inc. (BMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BioMarin Pharmaceutical Inc. (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals that treat serious diseases and medical conditions. The company offers products for the treatment of various diseases such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product portfolio consists of products and multiple clinical and preclinical product candidates. The company operates through its manufacturing facilities in Novato, California and has its presence in US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc. Key Recent Developments

Apr 28, 2016: BioMarin Announces First Quarter 2016 Financial Results
Feb 29, 2016: BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster
Feb 29, 2016: BioMarin Announces BioMarin RareConnections Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients
Jan 04, 2016: BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company's Board of Directors
Oct 29, 2015: BioMarin Announces Third Quarter 2015 Financial Results and Company Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

BioMarin Pharmaceutical Inc. - Key Facts
BioMarin Pharmaceutical Inc. - Key Employees
BioMarin Pharmaceutical Inc. - Key Employee Biographies
BioMarin Pharmaceutical Inc. - Major Products and Services
BioMarin Pharmaceutical Inc. - Pharmaceutical Pipeline Products Data
BioMarin Pharmaceutical Inc., Pipeline Products by Therapy Area
BioMarin Pharmaceutical Inc., Pipeline Products by Development Phase
BioMarin Pharmaceutical Inc. - Medical Equipment Pipeline Products Data
BioMarin Pharmaceutical Inc. Pipeline Products by Equipment Type
BioMarin Pharmaceutical Inc. - History
BioMarin Pharmaceutical Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BioMarin Pharmaceutical Inc. - Key Manufacturing Facilities
Joint Venture

SECTION 2 – COMPANY ANALYSIS

BioMarin Pharmaceutical Inc. - Business Description
BioMarin Pharmaceutical Inc. - Corporate Strategy
BioMarin Pharmaceutical Inc. - SWOT Analysis
SWOT Analysis - Overview
BioMarin Pharmaceutical Inc. - Strengths
Strength - Products for Rare Diseases
Strength - Research and Development Activities
Strength - Geographical Diversity
BioMarin Pharmaceutical Inc. - Weaknesses
Weakness - Declining Financial Performance
Weakness - Reliance on Limited Customer Base
BioMarin Pharmaceutical Inc. - Opportunities
Opportunity - Orphan Drug Designation
Opportunity - Product Pipeline
Opportunity - Product Acquisitions: Kuvan and Pegvaliase
BioMarin Pharmaceutical Inc. - Threats
Threat - Stringent Government Regulations
Threat - Competition in Drug Development
Threat - Uncertain R&D Outcomes
BioMarin Pharmaceutical Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 28, 2016: BioMarin Announces First Quarter 2016 Financial Results
Feb 29, 2016: BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster
Feb 29, 2016: BioMarin Announces BioMarin RareConnections Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients
Jan 04, 2016: BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company's Board of Directors
Oct 29, 2015: BioMarin Announces Third Quarter 2015 Financial Results and Company Update
Sep 30, 2015: Parent Project Muscular Dystrophy Launches Next Phase of Genetic Testing Program, Decode Duchenne in collaboration with BioMarin Pharmaceutical PTC Therapeutics, and Sarepta Therapeutics
Sep 01, 2015: BioMarin Launches kNOWyourDuchenne, Comprehensive Program for Patients With Duchenne Muscular Dystrophy to Understand Their Genetic Mutation
Aug 31, 2015: BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting
Aug 03, 2015: BioMarin Announces Second Quarter 2015 Financial Results and Company Update
Apr 30, 2015: BioMarin Announces First Quarter 2015 Financial Results and Company Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

BioMarin Pharmaceutical Inc., Key Facts
BioMarin Pharmaceutical Inc., Key Employees
BioMarin Pharmaceutical Inc., Key Employee Biographies
BioMarin Pharmaceutical Inc., Major Products and Services
BioMarin Pharmaceutical Inc., Number of Pipeline Products by Therapy Area
BioMarin Pharmaceutical Inc., Number of Pipeline Products by Development Stage
BioMarin Pharmaceutical Inc., Pipeline Products By Therapy Area and Development Phase
BioMarin Pharmaceutical Inc. Number of Pipeline Products by Equipment Type
BioMarin Pharmaceutical Inc. Pipeline Products by Equipment Type
BioMarin Pharmaceutical Inc. Pipeline Products by Development Stage
BioMarin Pharmaceutical Inc., History
BioMarin Pharmaceutical Inc., Other Locations
BioMarin Pharmaceutical Inc., Subsidiaries
BioMarin Pharmaceutical Inc., Key Manufacturing Facilities
BioMarin Pharmaceutical Inc., Joint Venture
BioMarin Pharmaceutical Inc., Key Competitors
BioMarin Pharmaceutical Inc., Ratios based on current share price
BioMarin Pharmaceutical Inc., Annual Ratios
BioMarin Pharmaceutical Inc., Interim Ratios
BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

BioMarin Pharmaceutical Inc., Pipeline Products by Therapy Area
BioMarin Pharmaceutical Inc., Pipeline Products by Development Phase
BioMarin Pharmaceutical Inc. Pipeline Products by Equipment Type
BioMarin Pharmaceutical Inc., Performance Chart (2011 - 2015)
BioMarin Pharmaceutical Inc., Ratio Charts
BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
BioMarin Pharmaceutical Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Tesaro, Inc.
Amicus Therapeutics, Inc.
Enzon Pharmaceuticals, Inc.
Biogen Idec Inc.
Protalix BioTherapeutics, Inc.
BioSpecifics Technologies Corp.
Shire Plc
Genzyme Corporation
Skip to top


Ask Your Question

BioMarin Pharmaceutical Inc. (BMRN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: